Revenue

Disconnected tech systems create 'invisible leakage' in psychiatric practices, fueling burnout. A new approach aims to unify the operational chaos.

Despite a Q3 net loss from market volatility and one-off costs, the energy firm declared its 51st straight dividend, banking on new acquisitions for growth.

Strong Q1 results driven by Australian operations and a record gas compression backlog, offsetting a cautious North American drilling market.

The medical device maker posts its 14th straight growth quarter, with soaring profits and a strategic focus on the underserved bronchiectasis market.

Chad Eberly's recent award highlights a shift in finance, where holistic support for SMBs is proving to be the new winning formula for growth.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

The industrial giant affirms its quarterly payout, a sign of stability for investors as it navigates a costly green transition and recent regulatory hurdles.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.

As BranchOut Food preps its Q1 earnings call, investors watch to see if its patented tech and retail wins can deliver on the path to profitability.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

Resideo posted strong Q1 results with an 8% revenue jump to $1.91B, setting a positive stage for the planned separation of its ADI distribution arm.

Explora Journeys' new LNG-powered ship blends sustainable travel with rare events like a solar eclipse, aiming to redefine luxury cruising in Northern Europe.

A new national survey reveals a crisis of trust in the American workplace, with widespread fear silencing employees and ethical pressures on the rise.

AWE 2026 honors XR legends, unveils groundbreaking art and research, and champions a future where spatial AI empowers, not replaces, humanity.

The California Science Center installs a massive 747 fuselage, offering a first look at the future Samuel Oschin Air and Space Center's grand vision.

Amity's retail AI agent beat 100+ firms to win a top award, proving that purpose-built vertical AI delivers more impact than generic chatbots.